TAT and neoplasm: CPPs, SynB3, Tat 47–57, and pVEC cross the BBB much more easily than do TP10 and TP10‐2 on account of their different structures.[20, 21, 22] Though drug delivery strategies based on CPPs can enhance BBB penetration, the application of CPPs is limited by its own nonselectivity, leading to a serious systemic toxicity in vivo.[23, 24] To enhance the tumor‐specificity of CPPs, it is ideal to combine the tumor targeting peptides (TTPs) to form an integrated drug‐loaded nanocarrier.[25, 26, 27]